http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106872593-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 |
| filingDate | 2017-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106872593-B |
| titleOfInvention | Application of lysophosphatidic acid as a marker in the detection of endometriosis |
| abstract | The invention discloses the application of lysophosphatidic acid as a biological marker in preparing a diagnostic reagent or a test for detecting endometriosis. Meanwhile, the present invention also provides a set of biomarkers for detecting endometriosis, consisting of the following six lysophosphatidic acids: 18:2 LPA; 16:0 LPA; 20:4 LPA; 18:1 LPA; 22:6 LPA; 18:0 LPA. The present invention adopts the ultra-high performance liquid chromatography-tandem mass spectrometry method to measure the levels of six kinds of LPA in the plasma of patients with endometriosis and normal controls, and the results show that the concentration levels of these six kinds of LPA in the plasma of patients with endometriosis significantly higher than that of normal controls. Therefore, these six LPAs can be used as biomarkers for endometriosis, and the sensitivity and specificity of these six LPAs as combined diagnostic markers are 92% and 86%, respectively, which are significantly higher than the current uterine Existing hematological biomarkers of endometriosis. |
| priorityDate | 2017-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 146.